Reset filter
Keywords
Neurology ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

1182 Search results.
Relevance Rating New first Old first

NINDS CDE Demographics Multiple Sclerosis - Demographics

- 3/15/21 - 1 form, 1 itemgroup, 8 items, 1 language
Itemgroup: Demographics
NINDS Common Data Elements, Multiple Sclerosis Demographics Used from the National Institute of Neurological Disorders and Stroke Common Data Elements (https://www.commondataelements.ninds.nih.gov/) References: Grinnon ST, Miller K, Marler JR, Lu Y, Stout A, Odenkirchen J, Kunitz S. National Institute of Neurological Disorders and Stroke Common Data Element Project - approach and methods. Clin Trials. 2012;9(3):322-9.

Demography Screening Ropinirole Parkinson Disease 101468/165 - Demography Screening

- 10/15/17 - 1 form, 1 itemgroup, 10 items, 1 language
Itemgroup: Demography
Study Part: Demography Screening. An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Eligibility Dementia NCT00294307

- 3/1/17 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Enhancing Care Coordination: Hospital to Home for Cognitively Impaired Older Adults and Their Caregivers; ODM derived from: https://clinicaltrials.gov/show/NCT00294307

Eligibility Parkinson's Disease NCT01268891

- 9/28/21 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea; ODM derived from: https://clinicaltrials.gov/show/NCT01268891

Anxiety And Depression Scale (HADS) Ropinirole Restless Legs Syndrom NCT00355641 - Anxiety And Depression Scale

- 9/27/21 - 1 form, 1 itemgroup, 1 item, 1 language
Itemgroup: Hospital anxiety and depression scale
Study part: Anxiety And Depression Scale. A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients with Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Clinicaltrials.gov Identifier: NCT00355641. Phase: phase 3. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP, Zygara; Zygara, ZIPEREVE, ZEPREVE, Requip Depot, REQUIP, REPREVE, Modutab, ADARTREL. Study Indication : Restless Legs Syndrome. Study ID: 101468/206. Clinical Study ID: 101468/206.

Vital Signs Follow- Up (Visit 10) Ropinirole Parkinson Disease 101468/165 - Vital Signs Follow- Up (Visit 10)

- 9/27/21 - 1 form, 1 itemgroup, 10 items, 1 language
Itemgroup: Vital Signs
Study Part: Vital Signs Follow- Up (Visit 10). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Urinalysis Test Results Follow- Up (Visit 10) Ropinirole Parkinson Disease 101468/165 - Urinalysis Test Results Follow- Up (Visit 10)

- 9/27/21 - 1 form, 2 itemgroups, 21 items, 1 language
Itemgroups: URINALYSIS TEST RESULTS, Dip stick
Study Part: Urinalysis Test Results Follow- Up (Visit 10). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Laboratory Collections Follow- Up (Visit 10) Ropinirole Parkinson Disease 101468/165 - Laboratory Collections Follow- Up (Visit 10)

- 9/27/21 - 1 form, 1 itemgroup, 5 items, 1 language
Itemgroup: clinical chemistry; haematology
Study Part: Laboratory Collections Follow- Up (Visit 10). An open-label, up-titration study to assess the dose proportionality of ropinirole controlled release (CR) and to demonstrate the bioequivalence of ropinirole CR (1 x 8 mg) compared to the ropinirole CR (4 x 2 mg) in Parkinson's Disease patients not receiving other dopaminergic therapies. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Phase: phase 2. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name: Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP,Zygara. Study Indication: Parkinson Disease. Study ID: 101468/165. Clinical Study ID: 101468/165

Visite 8 (Woche 24) TMP001 Multiple Sclerosis NCT02686788 - Visite 8 (Woche 24)

- 9/27/21 - 1 form, 11 itemgroups, 57 items, 1 language
Itemgroups: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Visite 8 (Woche 24). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Visite 7 (Woche 20) TMP001 Multiple Sclerosis NCT02686788 - Visite 7 (Woche 20)

- 9/27/21 - 1 form, 11 itemgroups, 57 items, 1 language
Itemgroups: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Visite 7 (Woche 20). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Visite 6 (Woche 16) TMP001 Multiple Sclerosis NCT02686788 - Visite 6 (Woche 16)

- 9/27/21 - 1 form, 11 itemgroups, 57 items, 1 language
Itemgroups: Administrative documentation, Vital signs; Body Temperature, study drug, Comorbidity, Adverse Events; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Visite 6 (Woche 16). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Baseline Visite (Visite 2/ Woche 0) TMP001 Multiple Sclerosis NCT02686788 - Baseline Visite (Visite 2/ Woche 0)

- 9/27/21 - 1 form, 10 itemgroups, 53 items, 1 language
Itemgroups: Administrative documentation, Vital signs; Body Temperature, Comorbidity; Exacerbation of multiple sclerosis, Physical examination, Urinalysis, Inclusion criteria; exclusion criteria, Laboratory, Blood sampling, Kurtzke Expanded Disability Status Scale Questionnaire, study drug
Study part: Baseline Visite (Visite 2/ Woche 0). TMP001 in Relapsing-remitting Multiple Sclerosis: A Multicentre Open, Baseline-controlled Phase IIa Clinical Trial.

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial